AI-powered, load-and-go platform has potential to radically shift how veterinarians process, diagnose, and act on cytology and blood morphology cases The global launch of the IDEXX (IDXX) inVue Dx ...
Double‑digit fourth‑quarter growth: IDEXX reported 14% reported (12% organic) revenue growth and $3.08 EPS (up 17% comparable), driven by record premium instrument placements (6,567 in the quarter, ...
Cancer Dx expansion and inVue Dx FNA combine preventive screening and rapid, in-clinic diagnosis, enabling veterinarians and pet owners to act with confidence The IDEXX inVue Dx analyzer, featuring a ...
Revenue Growth: 14% increase as reported and 12% organic growth in Q4 2025. CAG Diagnostics Recurring Revenue: 10% organic growth in Q4 2025. EPS: $3.08 in Q4 2025, up 17% year-over-year on a ...
Revenue for Q4 2024 was reported at $954 million, surpassing the estimate of $935 million. Q4 EPS came in at $2.62, exceeding the anticipated $2.40. The Companion Animal Group diagnostics segment ...
Cancer Dx expansion and inVue Dx FNA combine preventive screening and rapid, in-clinic diagnosis, enabling veterinarians and pet owners to act with confidence IDEXX Laboratories, Inc. (NASDAQ: IDXX), ...
The IDEXX Cancer Dx Panel has already transformed cancer screening for veterinarians. Today, more than 5,500 practices across the United States and Canada use the lymphoma test, which can detect the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results